Cargando…

Commentary on “CTLA-4 Blockade Suppresses Progression of Residual Tumours after Insufficient RFA”

Detalles Bibliográficos
Autores principales:	Geboers, B., Meijerink, M. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441074/ https://www.ncbi.nlm.nih.gov/pubmed/32710127 http://dx.doi.org/10.1007/s00270-020-02564-9

Ejemplares similares

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?
por: Su, David, et al.
Publicado: (2023)

Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration
por: Yoon, Jeong Hee, et al.
Publicado: (2018)

Commentary: Tricuspid insufficiency after heart transplant: More of an art than a science
por: Mehaffey, J. Hunter, et al.
Publicado: (2020)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

CTLA-4 Insufficiency due to a Novel CTLA-4 Deletion, Identified through Copy Number Variation Analysis
por: Olfe, Lisa, et al.
Publicado: (2022)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Radiotherapy induces responses of lung cancer to CTLA-4 blockade
por: Formenti, Silvia C., et al.
Publicado: (2018)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
por: Zhang, Shashuang, et al.
Publicado: (2020)

A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade
por: Philip, Hagit, et al.
Publicado: (2021)

Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours
por: Wah, Tze M, et al.
Publicado: (2014)

Acetyltransferases and tumour suppression
por: Phillips, A C, et al.
Publicado: (2000)

Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines
por: Miska, Jason, et al.
Publicado: (2018)

Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
por: Krausz, Máté, et al.
Publicado: (2022)

Alternative Test Systems RFA
Publicado: (1994)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
por: Youlin, Kuang, et al.
Publicado: (2012)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

CTLA-4 checkpoint blockade in breast cancer, a case in point report
por: Dellepiane, Chiara, et al.
Publicado: (2015)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
por: Zhou, Yifan, et al.
Publicado: (2022)

Cardiovascular and Interventional Radiological Society of Europe Commentary on the Treatment of Chronic Cerebrospinal Venous Insufficiency
por: Reekers, J. A., et al.
Publicado: (2010)

Point-Substitution of Phenylalanine Residues of 26RFa Neuropeptide: A Structure-Activity Relationship Study
por: Lefranc, Benjamin, et al.
Publicado: (2021)

Commentary: Newer modalities to prevent myopia progression
por: Tripathy, Koushik, et al.
Publicado: (2022)

Commentary: Curbing myopia progression: The way forward
por: Matalia, Jyoti, et al.
Publicado: (2022)

Corrigendum: Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
por: Krausz, Máté, et al.
Publicado: (2023)

Childhood brain tumour risk and its association with wireless phones: a commentary
por: Söderqvist, Fredrik, et al.
Publicado: (2011)

A commentary on the discrepancy between blood and tumour BRCA testing: An open question
por: De Paolis, Elisa, et al.
Publicado: (2022)

Laparoscopic RFA with splenectomy for hepatocellular carcinoma
por: Hu, Kunpeng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qdtcj0qh0if5hg9m77u1c4rkqf